Form 8-K - Current report:
SEC Accession No. 0001493152-25-003916
Filing Date
2025-01-28
Accepted
2025-01-28 08:30:32
Documents
14
Period of Report
2025-01-23
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 56261
2 ex99-1.htm EX-99.1 17968
  Complete submission text file 0001493152-25-003916.txt   259593

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cldi-20250123.xsd EX-101.SCH 3018
4 XBRL LABEL FILE cldi-20250123_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cldi-20250123_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3906
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 25561063
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)